Filing Analysis
⚠️ Delisting Notice
Filed May 08, 2026
🟠 HIGH
Cryo-Cell International received notice that NYSE Regulation accepted its compliance plan to regain standing with NYSE American listing standards. The company has been granted a plan period until September 9, 2027, to meet the requirements and avoid delisting.
🚩 Red Flags
- The company is currently in violation of NYSE American continued listing standards.
- The long duration of the compliance period (extending into late 2027) suggests significant financial or structural hurdles to overcome.
- Delisting risk remains if the company fails to make progress consistent with the accepted plan.
📋 Key Facts
- Notice of plan acceptance received from NYSE Regulation on May 6, 2026.
- The compliance plan was originally submitted by the company on April 8, 2026.
- The company has until September 9, 2027, to regain compliance with listing standards.
- Common stock (CCEL) will continue to trade on NYSE American during the plan period subject to periodic review.
- Failure to meet plan milestones or the final deadline may result in immediate delisting proceedings.
⚠️ Delisting Notice
Filed Mar 12, 2026
🟠 HIGH
Cryo-Cell International received a notice from NYSE American LLC on March 9, 2026, stating the company is not in compliance with continued listing standards under Section 1003(a). The company must submit a plan to regain compliance by April 8, 2026, to avoid potential delisting.
🚩 Red Flags
- Failure to satisfy continued listing standards.
- Risk of delisting if the compliance plan is not accepted or executed successfully.
- Potential underlying financial distress as Section 1003(a) often pertains to equity deficits or sustained losses.
📋 Key Facts
- Notice received from NYSE American on March 9, 2026.
- Non-compliance relates to Section 1003(a) of the NYSE American Company Guide.
- Deadline to submit a compliance plan is April 8, 2026.
- Common stock continues to trade on NYSE American under the symbol 'CCEL' during the plan review period.
- Section 1003(a) typically involves requirements regarding stockholders' equity and/or net losses.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.